Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 11, 2018
Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel diseaseMarkku Voutilainen, Nina Hutri-Kähönen, Päivi Tossavainen, et al.
The Journal of General Virology|December 5, 2025
Genoprevalence of cutavirus in benign and malignant intestinal and breast tissuesIrini M Assimakopoulou, Ushanandini Mohanraj, Taina Sipponen, et al.
Scandinavian Journal of Gastroenterology|August 23, 2022
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in ScandinaviaKristin H Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
Digestive Diseases and Sciences|March 24, 2016
Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective StudyAnastasios Koulaouzidis, Taina Sipponen, Artur Nemeth, et al.
Inflammatory Bowel Diseases|May 7, 2014
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remissionPauliina Molander, Martti Färkkilä, Kimmo Salminen, et al.
Heliyon|July 8, 2024
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatmentTero Ylisaukko-Oja, Clas-Göran Af Björkesten, Anja Eberl, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?Pauliina Molander, Martti Färkkilä, Ari Ristimäki, et al.
Scandinavian Journal of Gastroenterology|April 6, 2021
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in FinlandTaina Sipponen, Clas-Göran Af Björkesten, Taru Hallinen, et al.
Scandinavian Journal of Gastroenterology|June 12, 2019
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE)Anja Eberl, Taru Hallinen, Clas-Göran Af Björkesten, et al.
European Journal of Gastroenterology & Hepatology|February 19, 2025
Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort studyPauliina Molander, Clas-Göran Af Björkesten, Hans Henricson, et al.
Pageof 7